Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion
- Registration Number
- NCT00994734
- Lead Sponsor
- Gynuity Health Projects
- Brief Summary
The primary aim of this study is to assess the acceptability of home-use mifepristone for termination of pregnancy among women who choose it and their providers. The investigators' secondary aims are to assess rates of follow-up, adherence, efficacy, complications, lost productivity, and to estimate the minimum proportion of women who choose home-use over clinic use of mifepristone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 615
- Reproductive age women seeking abortion services.
- Eligible women will be in general good health and assessed by a clinician to have an intrauterine pregnancy less than 64 days L.M.P on the day mifepristone will be taken.
- Participants must be eligible for medical abortion according to clinician and clinic standards.
- In the United States, women only 18 years and older will be eligible to participate, unless the study site obtains a waiver to include minors.
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description home administration of mifepristone Mifepristone -
- Primary Outcome Measures
Name Time Method Proportion of women who select home-use of mifepristone 1-2 weeks Satisfaction with Method 1-2 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
Municipal Clinical Hospital
🇲🇩Chisinau, Moldova, Republic of
Kathmandu Medical College
🇳🇵Kathmandu, Nepal
Nepal Medical College Teaching Hospital
🇳🇵Kathmandu, Nepal
Institute for Family Health
🇺🇸New York, New York, United States
Feminist Women's Health Center
🇺🇸Atlanta, Georgia, United States
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Family Health Center, Montefiore Medical Center
🇺🇸Bronx, New York, United States